Hematological Disorders
Sanofi gears up for approval of its BTK inhibitor, meets Phase III endpoint
Sanofi’s rilzabrutinib has found success and met the primary endpoint in the Phase III LUNA trial in heavily pre-treated immune…
Eilean receives Australian HREC approval to begin Phase I AML trial
Eilean Therapeutics has received approval from the Human Research Ethics Committee (HREC) in Australia to commence a Phase I clinical…
Arovella Therapeutics to raise funds for trial of lymphoma drug
Australian biotechnology company Arovella Therapeutics has announced plans to raise around A$12.5m ($8.1m) to begin Phase I clinical trials of…
Takeda reports interim findings from immune thrombocytopenia trial
Takeda has reported positive interim data from a Phase II clinical trial of mezagitamab (TAK-079) in patients with persistent or…
InnoCare receives clearance for leukaemia/lymphoma trial in China
InnoCare Pharma has received clearance for an investigational new drug application to conduct a clinical trial of ICP-248 plus orelabrutinib…
GSK reports positive data from Phase III multiple myeloma trial
GSK has reported positive interim headline data from the Phase III DREAMM-8 clinical trial of Blenrep (belantamab mafodotin) for the…
Ryvu Therapeutics begins Phase II leukaemia treatment trial
Ryvu Therapeutics has initiated a Phase II clinical trial of RVU120, dosing the first patient with relapsed/refractory acute myeloid leukaemia…
Grifols gears up for FDA approval of fibrinogen replacement therapy
Spanish pharmaceutical company Grifols has reported positive Phase III trial data for its fibrinogen concentrate, AdFIrst (BT524) as a treatment…
Hemab reports positive Phase I Glanzmann thrombasthenia therapy data
Hemab Therapeutics has released initial positive data from the Phase I portion of its Phase I/II trial of HMB-001, a…
FDA puts Gilead’s magrolimab trials on clinical hold
The US Food and Drug Administration (FDA) has placed a full clinical hold on all the clinical trials of Gilead…
